Compare CLFD & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | LCTX |
|---|---|---|
| Founded | 1979 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.7M | 301.7M |
| IPO Year | 1995 | 1996 |
| Metric | CLFD | LCTX |
|---|---|---|
| Price | $29.27 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $43.50 | $6.25 |
| AVG Volume (30 Days) | 206.3K | ★ 839.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $85,034,000.00 | $14,556,000.00 |
| Revenue This Year | $11.64 | $109.40 |
| Revenue Next Year | $22.30 | N/A |
| P/E Ratio | $214.00 | ★ N/A |
| Revenue Growth | 9.51 | ★ 53.24 |
| 52 Week Low | $23.76 | $1.00 |
| 52 Week High | $52.73 | $2.09 |
| Indicator | CLFD | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 53.23 |
| Support Level | $28.26 | $1.02 |
| Resistance Level | $30.99 | $1.18 |
| Average True Range (ATR) | 1.16 | 0.05 |
| MACD | 0.40 | 0.01 |
| Stochastic Oscillator | 74.33 | 68.62 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.